Deals Of The Week: UCSF Catalyzes R&D Tech-Transfer Deals With Private Sector
Executive Summary
Through the Catalyst Awards program at its Clinical and Translational Science Institute, UCSF will give MedImmune access to a broad range of discovery and preclinical opportunities under a three-year agreement. Plus, Mallinckrodt buys Cadence, Debiopharm acquires Affinium’s antibiotics program, and more.
You may also be interested in...
Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?
After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.
Commercial Fate Of Sarepta’s DMD Gene Therapy Remains Tied To EMBARK
The company guided investors to expect a narrow initial label under a US FDA accelerated approval for SRP-9001, with expansion possible based on EMBARK.